Literature DB >> 3363182

Chronotropic actions of cholecystokinin octapeptide on the rat heart.

J D Marker1, M L Roberts.   

Abstract

Cholecystokinin octapeptide (CCK-8) administered i.v. to urethane-anaesthetized rats or added to the perfusion stream of isolated rat hearts produced an immediate bradycardia. The size of this response was dose-related. Studies in vivo and in vitro using atropine and propranolol indicated that the response to CCK-8 was largely due to a direct action of the peptide on the heart. N-carbobenzoxy-tryptophan (CBZ-Trp), a cholecystokinin receptor antagonist, abolished the response of the isolated heart to CCK-8. Gastrin I did not produce bradycardia. The receptors on rat heart were similar to the classes of cholecystokinin receptors found in brain and exocrine pancreas in that CCK-8 rather than cholecystokinin tetrapeptide (CCK-4) was the preferred agonist.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3363182     DOI: 10.1016/0167-0115(88)90081-x

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  4 in total

1.  Mechanisms contributing to the differential haemodynamic effects of bombesin and cholecystokinin in conscious, Long Evans rats.

Authors:  P J Janssen; S M Gardiner; A M Compton; T Bennett
Journal:  Br J Pharmacol       Date:  1991-01       Impact factor: 8.739

2.  Cholecystokinin octapeptide improves cardiac function by activating cholecystokinin octapeptide receptor in endotoxic shock rats.

Authors:  Xiao-Yun Zhao; Yi-Ling Ling; Yu-Guang Li; Ai-Hong Meng; Han-Ying Xing
Journal:  World J Gastroenterol       Date:  2005-06-14       Impact factor: 5.742

3.  Roles for CCK1 and 5-HT3 receptors in the effects of CCK on presympathetic vasomotor neuronal discharge in the rat.

Authors:  Mitsuhiko Saita; Anthony J M Verberne
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

4.  Characterization of the receptors and mechanisms involved in the cardiovascular actions of sCCK-8 in the pithed rat.

Authors:  A J Gaw; D M Hills; C F Spraggs
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.